Standout Papers

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorec... 2008 2026 2014 2020 1.2k
  1. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer (2008)
    Federica Di Nicolantonio, Miriam Martini et al. Journal of Clinical Oncology
  2. PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies (2009)
    Andrea Sartore‐Bianchi, Miriam Martini et al. Cancer Research

Immediate Impact

6 by Nobel laureates 39 from Science/Nature 112 standout
Sub-graph 1 of 14

Citing Papers

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
2023 Standout
Genetic and biological hallmarks of colorectal cancer
2021 Standout
11 intermediate papers

Works of Francesca Molinari being referenced

Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
2010
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
2008 Standout
and 6 more

Author Peers

Author Last Decade Papers Cites
Francesca Molinari 3036 1475 1508 52 4.6k
Silvio Veronese 3546 1565 1975 89 5.3k
Miriam Martini 2317 2080 991 44 4.4k
Dirk Laurent 2896 1501 1450 76 4.5k
Gorana Tomasic 4340 1661 1383 63 5.9k
Tamás Pintér 4506 892 2616 50 5.7k
Christopher R. Garrett 2754 1369 2358 49 5.2k
Gunter Schuch 2719 1763 1485 68 4.9k
Piercarlo Saletti 4167 1005 2040 74 5.4k
Xiaoyun Liao 4214 1512 1765 67 6.1k
Gaia Schiavon 2504 1490 1661 104 4.5k

All Works

Loading papers...

Rankless by CCL
2026